LEAMINGTON, ON, Dec. 20, 2018 /CNW/ – Aphria Inc. announced that the Company has completed its second shipment of approximately 80 L (equivalent to approximately 20 kg of dried bud) of medical cannabis to its Australian-based partner Althea Company Pty Ltd. (“Althea“).
Under a previously announced supply agreement with Althea (the “Agreement“), Aphria is providing packaged co-branded cannabis oil and dried flower products for the Australian medical cannabis market. Prior to shipment, the Australian Governments’ Office of Drug Control issued an import certificate and Health Canada issued an export certificate.
“We are thrilled to complete this second shipment and by the fast-growing demand for Aphria co-branded medical cannabis in Australia,” said Jakob Ripshtein, President of Aphria. “Through investments and valuable partners like Althea, Aphria continues to execute on its strategic plan for international expansion, growing our presence in high-value global markets.”
This is the second shipment Aphria has made to Althea as part of the Agreement, with each successive shipment expected to increase in volume. The shipment included a mix of cannabis oil and dried bud products, Rideau, Jasper, Capilano, Champlain and Henik which Althea is making available for distribution to pharmacies for eligible medical cannabis patients in Australia. Aphria completed its first shipment of medical cannabis, including approximately 60 L of cannabis oil (equivalent to approximately 10 kg of dried bud), to Althea in April 2018. Permits for a third shipment have already been lodged due to a sharp increase in demand.
In addition to the Agreement, Aphria maintains its 25% ownership interest in Althea. Today, Aphria’s global presence extends across Canada, Europe, Latin America, the Caribbean, Africa and Oceania.
We Have a Good Thing Growing.
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.